Amgen Inc. closed 16.06% short of its 52-week high of $346.85, which the company reached on July 25th.

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m. ET on Wednesday, Feb. 19, 2025. Jean-Charles Soria, senior vice president of oncology within global ...

While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...

Gladstone Institutional Advisory LLC trimmed its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 18.9% in the fourth ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Free cash flow surged to $4.4 billion, up a remarkable 1,367% year over year. Amgen reported strong fourth-quarter earnings, ...

Citi analyst Geoff Meacham maintained a Hold rating on Amgen (AMGN – Research Report) today and set a price target of $295.00. The company’s ...

All of a sudden, Amgen stock is up 15% since late December to around $299. Its rise helped push up the healthcare sector up ...

Amgen Inc.'s ( NASDAQ:AMGN ) dividend will be increasing from last year's payment of the same period to $2.38 on 7th ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...